Home>Video>A Wide-Moat Opportunity in Health Care

A Wide-Moat Opportunity in Health Care

Wed, 11 Mar 2015

Actavis' transformation to a wide-moat company following its deal with Allergan represents a good buying opportunity for long-term investors.

+

Video Transcript

Michael Waterhouse: We think Actavis' transformation to a wide-moat company represents a good buying opportunity for long-term shareholders. This company has dramatically changed over the last few years from a small generic-drug manufacturer to a very large branded-pharmaceutical firm with pro forma sales after the Allergan (AGN) deal on par with big players like Eli Lilly (LLY) and GlaxoSmithKline (GSK).

We like the business and we give it a wide moat for three primary reasons. The first is that we think the business will be very diversified. The largest product, Botox, will be about 10% of sales; but below that, no single product will be more than 5% of the franchise. So, there's no big risk of any patent loss really hitting earnings hard.

The second reason is we think that the products have a very long lifecycle. A lot of the major products like Botox and Restasis have very little risk of branded and generic competition, which should provide a long life of cash flows. And then third, we really like the pipeline. Granted, a lot of that is inherited from Allergan, but we think there is a lot of growth potential--especially in ophthalmology--from those products in development.

We think Actavis remains undervalued. We think the company will create over $8 billion in free cash flow annually, and earnings per share should hit $23 by 2017, based on cost synergies from the recent Allergan deal. We currently have a $330 fair value estimate on the stock, which is currently in 4-star territory. And even though the stock has had a run earlier this year, we still think there is plenty of room for appreciation.

  1. Related Videos
  2. Related Articles
  1. Why Moats Matter

    An economic moat provides a gauge of a company's competitive advantages and overall strength, and it is a highly valuable tool for investors of all levels.

  2. An All-in-One Utilities Investment for Your Watchlist

    Wide - moat Dominion Resources is slightly overvalued at present, but with strong earnings growth potential and a reliable management team, it's a stock that investors should keep an eye on.

  3. The Friday Five

    Still gas in the tank for Apple, Facebook gets mobile mojo, a possible wide - moat combination, and more.

  4. Friday Five: Heinz-Kraft Deal Makes for a Tasty Combo

    The packaged-foods merger makes sense from a strategic standpoint, says Morningstar markets editor Jeremy Glaser. Plus, the Fed guessing game continues, and more.

  5. The Friday Five

    Five stats from the market and the stories behind them. This week: three wide - moat names worth a look, an 89-day deal in Washington, and more.

  6. 5 Wide -Moat Stocks That Were Left Behind in 2014

    It was a good year for wide - moat stocks overall, but Exxon, Amazon, and a few others lagged the market, says Morningstar markets editor Jeremy Glaser.

  7. Picks and Strategies to Navigate Today's Market

    Roundtable report: Morningstar strategists offer up their best ideas for a fully valued, low-yield market with few attractive choices.

  8. Separate Signal From Noise in the Debt Ceiling Debate

    Investors should focus on a suitable overall allocation but otherwise resist making short-term trades around this highly uncertain and potentially volatile D.C. drama, says Morningstar markets editor Jeremy Glaser.

©2017 Morningstar Advisor. All right reserved.